Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess the efficacy and safety of monthly injections of Omalizumab
150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive
to convetional therapy by antihistamins or oral corticosteroids.